Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 74

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 74
---
,
reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the initial
Business Combination and (ii) with respect to the remaining 50% of the Founder Shares and the Private Placement Units, six months after
the date of the consummation of the initial Business Combination, or earlier, in either case, if, subsequent to the initial Business
Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction which results in all of the shareholders
having the right to exchange their ordinary shares for cash, securities or other property.

Administrative
Support Agreement

The
Company has entered into an administrative services agreement, effective on January 7, 2025, pursuant to which the Company has agreed
to pay the Sponsor or an affiliate $10,000 for office space, and administrative and support services. Upon completion of the initial
Business Combination or the Company’s liquidation, the administrative services agreement will terminate, and the Company will cease
paying these monthly fees. For the three and nine months ended September 30, 2025, the Company incurred $30,000 and $81,000 in administrative
support fees and included in general and administrative costs on the unaudited statements of operations. As of September 30, 2025, $81,000
was recorded as a reduction in share subscription receivable on the unaudited balance sheets. For the period from May 23, 2024 (inception)
through September 30, 2024, we did not incur fees for these services.

12

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

Promissory
Note — Related Party

On
June 13, 2024, the Sponsor issued an unsecured promissory note to the Company (the “Promissory Note”), pursuant to which
the Company may borrow up to an aggregate principal amount of $500,000. On November 21, 2024, the Sponsor amended the Promissory Note
to increase the amount the Company may borrow to $750,000. On December 5, 2024, the Sponsor further amended the Promissory Note to increase
the amount the Company may borrow to $1,850,000. The Promissory Note is non